SCHEMBL1192148

SCHEMBL1192148

C[C@H]1C[C@@H](N(Cc2ccccc2)Cc2ccccc2)CC[C@H]1O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC18A3 Q16572 2/20 0.44
YTHDC1 Q96MU7 1/20 0.42
SLC6A2 P23975 2/20 0.41
SLC6A4 P31645 2/20 0.41
MAPT P10636 1/20 0.41
SLC6A3 Q01959 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
GRIN2B Q13224 1/20 0.38
RAB9A P51151 1/20 0.38
DPP8 Q6V1X1 1/20 0.38
DPP7 Q9UHL4 1/20 0.38
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
FUCA1 P04066 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12466177 1.00 SLC18A3 (0.44) SLC18A3YTHDC1SLC6A2SLC6A4MAPT
SCHEMBL1192262 1.00 SLC18A3 (0.44) SLC18A3YTHDC1SLC6A2SLC6A4MAPT
SCHEMBL12468294 1.00 SLC18A3 (0.44) SLC18A3YTHDC1SLC6A2SLC6A4MAPT
SCHEMBL15065296 0.81 YTHDC1 (0.42) YTHDC1SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL12465971 0.81 YTHDC1 (0.42) YTHDC1SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL27938356 0.81 YTHDC1 (0.42) YTHDC1SLC6A2SLC6A4SLC6A3KMT2A
SCHEMBL25341885 0.80 YTHDC1 (0.49) SLC18A3YTHDC1SLC6A2SLC6A4SLC6A3
SCHEMBL23583787 0.80 YTHDC1 (0.46) SLC18A3YTHDC1SLC6A2SLC6A4SLC6A3
SCHEMBL25111999 0.80 YTHDC1 (0.49) SLC18A3YTHDC1SLC6A2SLC6A4SLC6A3
SCHEMBL23329113 0.80 YTHDC1 (0.49) SLC18A3YTHDC1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459535-B1 PYRIDINE AND PYRAZINE DERIVATIVES AS PROTEIN KINASE MODULATORS NOVARTIS AG (CH) 2015-03-25 EP disclosed
US-20140288076-A1 HETEROARYL COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2014-09-25 US disclosed
US-8778951-B2 Heteroaryl compounds and their uses NOVARTIS AG (CH) 2014-07-15 US disclosed
US-20130303507-A1 SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2013-11-14 US disclosed
US-20130172354-A1 HETEROARYL COMPOUNDS AND THEIR USES NOVARTIS AG (CH) 2013-07-04 US disclosed
US-8415381-B2 Heteroaryl compounds and their uses NOVARTIS AG (CH) 2013-04-09 US disclosed
US-20110028492-A1 Heteroaryl Compounds and Their Uses NOVARTIS AG (CH) 2011-02-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130172354-A1 HETEROARYL COMPOUNDS AND THEIR USES CDK9, CDK19, CDK3 SLC18A3 4286/4885YTHDC1 4199/4885SLC6A2 3437/4885
US-20140288076-A1 HETEROARYL COMPOUNDS AND THEIR USES CDK9, CDK19, CDK3 SLC18A3 4286/4885YTHDC1 4199/4885SLC6A2 3437/4885
US-20110028492-A1 Heteroaryl Compounds and Their Uses CDK9, CDK19, CDK3 SLC18A3 4286/4885YTHDC1 4199/4885SLC6A2 3437/4885
US-20130303507-A1 SUBSTITUTED HETERO-BIARYL COMPOUNDS AND THEIR USES CDK9, CDK19, CDK3 SLC18A3 4773/4885YTHDC1 4459/4885SLC6A2 4440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.